Exploring European consensus about the remaining treatment challenges and subsequent opportunities to improve the management of Invasive Fungal Infection (IFI) in the Intensive Care Unit.

Abstract

Abstract Background:The global prevalence of invasive fungal infections (IFI) is increasing, particularly within Intensive Care Units (ICU), where Candida spp. and Aspergillusspp. represent the most important pathogens. Diagnosis and management of IFIs becomes progressively challenging, with increasing antifungal resistance and the emergence of rare fungal species. The aim of this project was to identify challenges around diagnosing and managing IFIs in the ICU through a consensus survey focused on assessing current views on how IFI should be managed, the current status in different countries and perceived challenges to date amongst a multidisciplinary cohort of healthcare professionals involved in the care of IFI in the ICU. Methods: Using a modified Delphi approach, an expert panel developed 44 Likert scale statements across 6 key domains concerning patient screening and minimal standards for diagnosis of IFIs in ICU; initiation and termination of antifungal treatments and how to minimise their side effects and insights for future research on this topic. These were used to develop an online survey which was distributed on a convenience sampling basis utilising the subscriber list held by an independent provider (M3 Global). This survey was distributed to intensivists, infectious disease specialists, microbiologists and antimicrobial/ICU pharmacists within the UK, Germany, Spain, France and Italy. The threshold for consensus was set at 75%. Results: A total of 335 responses were received during the five-month period to collect responses. From these, 29/44 (66%) statements attained very high agreement (≥90%), 11/44 (25%) high agreement (<90% and ≥75%), and 4/44 (9%) did not meet threshold for consensus (<75%). Conclusion: The results outline the need for physicians to be aware of the local incidence of IFI and the associated rate of azole resistance in their ICUs. Where high clinical suspicion exists, treatment should start immediately and prior to receiving the results from any diagnostic test. Beta-D-glucan testing should be available to all ICU centres, with results available within 48 hours, in order to inform the cessation of empirical antifungal therapy. These consensus statements and proposed measures may guide future areas for further research to optimise the management of IFIs in the ICU.